Effect of genistein on p90RSK phosphorylation and cell proliferation in T47D breast cancer cells

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 209-214

  Gwin, John ^a   Drews, Neil ^a   Ali, Syed ^a   Stamschror, Justin ^a   Sorenson, Matthew ^a   Rajah, Talitha T ^a  

^a DEPAUL UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell proliferation; Genistein; p90RSK; T47d cells

Indexed keywords

GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; P90 RIBOSOMAL S6 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL COMMUNICATION; CELL PROLIFERATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL;

ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENISTEIN; HUMANS; PHOSPHORYLATION; RECEPTORS, ESTROGEN; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 79851494850     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S and Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinol 138: 863-870, 1997. (Pubitemid 27089735)
2. Rajah TT, Du N, Drews N and Cohn R: Genistein in the presence of 17β-estradiol inhibits proliferation of ERβ breast cancer cells. Pharmacology 84: 68-73, 2009.
3. Hseih CY, Santell RC, Haslam SZ and Helferich WG: Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF7) cells in vitro and in vivo. Cancer Res 58: 3833-3838, 1998. (Pubitemid 28405638)
4. Messina M, McCaskill-Stevens W and Lampe JW: Addressing the soy and breast cancer relationship: review, commentary and workshop proceedings. J Natl Cancer Inst 98: 1275-1284, 2006. (Pubitemid 44530723)
5. Sotoca AM, Ratman D, van der Saag P, Strom A, Gustafsson JA, Vervoort J, Rietjens IMCM and Murk AJ: Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERα/ERβ ratio. J Steroid Biochem Mol Biol 112: 171-178, 2008.
6. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J and Gustafsson JA: Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101: 1566-1571, 2004. (Pubitemid 38236167)
7. Belcher SM and Zsamovszky A: Estrogenic actions in the brain: estrogen, phytoestrogens and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 299: 408-414, 2001. (Pubitemid 32979650)
8. Kampa M, Pelekanou V and Castanas E: Membrane-initiated steroid action in breast and prostate cancer. Steroids 73: 953-960, 2008.
9. Whyte J, Bergin O, Bianchi A, McNally S and Martin F: Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 11(5): 209, 2009.
10. Prifti S, Mall P, Strowitzki T and Rabe T: Synthetic estrogens-mediated activation of JNK intracellular signaling molecule. Gynecol Endocrinol 15: 135-141, 2001. (Pubitemid 32423254)
11. Altiok N, Koyuturk M and Altiok S: JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells. Breast Cancer Res Treat 105: 247-254, 2007. (Pubitemid 47596440)
12. Lewis-Wambi JS and Jordan VC: Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11(3): 206, 2009.
13. Cogswell PC, Guttridge DC, Funkhouser WK and Baldwin AS Jr.: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19: 1123-1131, 2000. (Pubitemid 30157541)
14. Clarkson RW and Watson CJ: NF-kappa B and apoptosis in mammary epithelial cells. J Mammary Gland Biol Neoplasia 4: 165-175, 1999.
15. Osipo C, Gajdos C, Liu H, Chen B and Jordan VC: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95: 1597-1608, 2003.
16. Johnson FM, Saigal B, Tran H and Donato NJ: Abrogation of signal transducer and activator of transcription 3 reactivation after src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 13: 4233-4244, 2007. (Pubitemid 47105988)
17. Kang KN, Lee KW, Rogozin EA, Cho Y-Y, Heo Y-S, Bode AM, Lee HJ and Dong Z: Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic transformation by targeting the MEK7ERK/p90RSK/activator protein-1 pathway. J Biol Chem 282: 32856-32866, 2007. (Pubitemid 350159319)
18. Nguyen TL: Targeting RSK: An overview of small molecule inhibitors. Anticancer Agents Med Chem 8: 710-716, 2008.
19. Frodin M and Gammeltoft S: Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151: 65-77, 1999.
20. Dampler K, Hudson EA, Howells LM, Manson MM, Walker RA and Gescher A: Differences between human breast cell line in susceptibility towards growth inhibition by genistein. Br J Cancer 85: 618-624, 2001. (Pubitemid 32808289)
21. Liu H, Du J, Hu C, Qi H, Wang X, Wang S, Liu Q and Li Z: Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-α- mediated transcription in MCF-7 breast cancer cells. J Nutr Biochem 21: 390-396, 2010.
22. 2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol 24: 401-409, 2008.
23. Kim SH, Kim SH, Kim YB, Jeon YT, Lee SC and Song YS: Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann NY Acad Sci 1171: 495-500, 2009.
24. 2: a new redox sensitive pathway. Circulation 95: 1-220, Abstract, 1998.
25. Sauer H, Klimm B, Hescheler J and Wartenberg M: Activation of p90RSK and growth stimulation of multicellular tumor spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. FASEB J 15: 2539-2541, 2001.
26. Banerjee S, Li Y, Wang Z and Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Lett 269: 226-242, 2008.
27. Ray G, Batra S, Shukla NK, Deo S, Raina C, Ashok S and Husain SA: Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 59: 163-170, 2000. (Pubitemid 30216139)
28. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, Coombes RC and Ali S: Phosphorylation of estrogen receptor-α at Ser 167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res 13: 5769-5776, 2007. (Pubitemid 47583902)
29. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF and Mabry TJ: Flavonoid effects relevant to cancer. J Nutr 132: 3482S-3489S, 2002.
30. Davis DD, Diaz-Cruz ES, Landini S, Kim YW and Brueggemeier RW: Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol 108: 23-31, 2008. (Pubitemid 351173827)
31. Jeune MAK, Diaka JK and Brown J: Anticancer activities of pomegranate and genistein in human breast cancer cells. J Med Food 8: 469-475, 2005.